PBMs To FDA: Prohibit Brand Drug Makers From Filing Citizen Petitions

The pharmacy benefit manager (PBM) lobby is proposing FDA prohibit brand drug makers from filing citizen petitions, except for situations involving urgent health issues, in order to curb anticompetitive behavior by the brand-drug industry. The group maintains there are other ways brand companies can contact FDA should they have valid scientific issues or questions about a generic drug application. In comments submitted to FDA in early December, the Pharmaceutical Care Management Association (PCMA) expresses strong support for the agency’s draft...